WhaleCreep

Avidity Partners Management LP 13F holdings, Q3 2023

Hedge fundSEC filingsCompare with another fundHoldings as of 2023-09-30, filed 2023-11-14

Avidity Partners Management LP disclosed 83 US equity positions worth $2.5bn in its Q3 2023 13F filing. Its largest position is BSX at 4.4% of the reported book, followed by JAZZ and BDX. Versus Q2 2023 it opened 13 new positions, added to 24, reduced 44 and exited 23.

$2.5bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
83
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
4.4%
Largest position
The largest single position as a share of the reported equity book.
29.6%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
53
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q2 2023: 13 new, 24 added, 44 reduced, 23 exited

50 of 83
BSX BOSTON SCIENTIFIC CORPHealthcare4.4%$109m2.07m+163%added
JAZZ JAZZ PHARMACEUTICALS PLCHealthcare4.2%$103m797,500+13%added
BDX BECTON DICKINSON & COHealthcare3.0%$74.1m286,800−28%reduced
NBIX NEUROCRINE BIOSCIENCES INCHealthcare3.0%$73.4m652,100−2.0%reduced
MCK MCKESSON CORPHealthcare2.9%$72.3m166,300+64%added
LEGN LEGEND BIOTECH CORPHealthcare2.6%$65.0m967,000+21%added
THC TENET HEALTHCARE CORPHealthcare2.6%$63.5m963,800−2.7%reduced
CI THE CIGNA GROUPHealthcare2.4%$59.4m207,700–new
IDYA IDEAYA BIOSCIENCES INCHealthcare2.3%$57.9m2.14m−28%reduced
UNH UNITEDHEALTH GROUP INCHealthcare2.3%$56.6m112,200–new
SRPT SAREPTA THERAPEUTICS INCHealthcare2.2%$54.5m450,000+51%added
HUM HUMANA INCHealthcare2.2%$53.7m110,300–new
ARVN ARVINAS INCHealthcare2.1%$51.4m2.61m−5.7%reduced
ACHC ACADIA HEALTHCARE COMPANY INHealthcare2.0%$50.3m715,000+30%added
KRTX KARUNA THERAPEUTICS INC–2.0%$48.5m286,700−35%reduced
REGN REGENERON PHARMACEUTICALSHealthcare1.9%$47.7m58,000+134%added
ZTS ZOETIS INCHealthcare1.8%$45.6m262,100+21%added
IMVT IMMUNOVANT INCHealthcare1.8%$45.1m1.17m−44%reduced
MLTX MOONLAKE IMMUNOTHERAPEUTICSHealthcare1.8%$44.3m777,172+94%added
DHR DANAHER CORP DELHealthcare1.8%$43.8m176,600–new
ZNTL ZENTALIS PHARMACEUTICALS INCHealthcare1.7%$42.1m2.10m−10%reduced
ITCIEUR INTRA-CELLULAR THERAPIES INC–1.7%$41.7m801,100–new
SNDX SYNDAX PHARMACEUTICALS INCHealthcare1.6%$41.0m2.82m−1.8%reduced
LLY ELI LILLY & COHealthcare1.6%$40.3m75,000−44%reduced
NTRA NATERA INCHealthcare1.6%$39.8m899,000+108%added
ARGX ARGENX SEHealthcare1.6%$39.6m80,600−56%reduced
SGRY SURGERY PARTNERS INCHealthcare1.6%$39.1m1.34m−14%reduced
LNTH LANTHEUS HLDGS INCHealthcare1.6%$38.8m558,400+128%added
PCVX VAXCYTE INCHealthcare1.6%$38.5m756,165−14%reduced
2655787D BLUEPRINT MEDICINES CORP–1.5%$37.7m751,600+81%added
AKROEUR AKERO THERAPEUTICS INC–1.5%$37.4m739,100−28%reduced
MIRM MIRUM PHARMACEUTICALS INCHealthcare1.5%$36.1m1.14m–new
PRVA PRIVIA HEALTH GROUP INCHealthcare1.4%$35.5m1.55m+43%added
DXCM DEXCOM INCHealthcare1.4%$35.2m377,700–new
BHVN BIOHAVEN LTDHealthcare1.3%$33.4m1.29m−3.0%reduced
RCKT ROCKET PHARMACEUTICALS INCHealthcare1.3%$32.5m1.59m+20%added
AMLX AMYLYX PHARMACEUTICALS INCHealthcare1.3%$32.2m1.76m+95%added
IMGNEUR IMMUNOGEN INC–1.2%$30.4m1.92m−4.0%reduced
BIIB BIOGEN INCHealthcare1.2%$29.7m115,400−34%reduced
CRBU CARIBOU BIOSCIENCES INCHealthcare1.2%$28.9m6.05m+119%added
ARWR ARROWHEAD PHARMACEUTICALS INHealthcare1.2%$28.6m1.06m+15%added
HCA HCA HEALTHCARE INCHealthcare1.1%$28.2m114,800–new
NMRA NEUMORA THERAPEUTICS INC.Healthcare1.0%$25.4m1.80m–new
GPCR STRUCTURE THERAPEUTICS INCHealthcare1.0%$25.2m500,000+1223%added
UHS UNIVERSAL HLTH SVCS INCHealthcare0.9%$22.9m182,000−51%reduced
CUREVAC N V no ticker–0.9%$21.3m3.12m−28%reduced
AXSM AXSOME THERAPEUTICS INC.Healthcare0.8%$20.7m296,800−46%reduced
RARE ULTRAGENYX PHARMACEUTICAL INHealthcare0.8%$19.4m544,000−40%reduced
PRTA PROTHENA CORP PLCHealthcare0.7%$18.4m382,305−29%reduced
RVMD REVOLUTION MEDICINES INCHealthcare0.7%$18.2m657,200−39%reduced

Exited since Q2 2023

23 rows
GEHC GE HEALTHCARE TECHNOLOGIES I3.0%$84.9m
ABBV ABBVIE INC2.4%$69.8m
BIO BIO RAD LABS INC2.0%$57.9m
COR CENCORA INC2.0%$57.7m
APLSUSD APELLIS PHARMACEUTICALS INC1.5%$42.7m
PFE PFIZER INC1.4%$41.0m
VIR VIR BIOTECHNOLOGY INC1.2%$35.0m
BAX BAXTER INTL INC1.0%$27.6m
EDIT EDITAS MEDICINE INC0.9%$24.7m
AXNX* AXONICS INC0.7%$19.2m
PLRX PLIANT THERAPEUTICS INC0.6%$16.6m
SLRN ACELYRIN INC0.5%$15.7m
POINT BIOPHARMA GLOBAL INC no ticker0.5%$15.1m
TSVT* 2SEVENTY BIO INC0.5%$13.6m
MLYS MINERALYS THERAPEUTICS INC0.5%$13.1m
MERSANA THERAPEUTICS INC no ticker0.4%$12.5m
NARIUSD INARI MED INC0.4%$10.2m
ETNBGBP 89BIO INC0.3%$10.0m
DNLI DENALI THERAPEUTICS INC0.3%$8.3m
SLP SIMULATIONS PLUS INC0.07%$2.0m
BHC BAUSCH HEALTH COS INC0.06%$1.7m
EXAIEUR EXSCIENTIA PLC0.03%$755k
AIP ARTERIS INC0.02%$515k

Sector mix

  • Healthcare86.3%
  • Unclassified13.7%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters